X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ORCHID PHARMA LTD ELDER PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x -0.2 -0.2 - View Chart
P/BV x 0.1 0.2 63.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ORCHID PHARMA LTD
Sep-13
ELDER PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs380194 195.9%   
Low Rs18835 537.1%   
Sales per share (Unadj.) Rs491.2276.5 177.7%  
Earnings per share (Unadj.) Rs-3.2-79.2 4.0%  
Cash flow per share (Unadj.) Rs14.4-43.5 -33.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.553.9 698.0%  
Shares outstanding (eoy) m20.5470.45 29.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.60.4 139.6%   
Avg P/E ratio x-89.3-1.4 6,175.1%  
P/CF ratio (eoy) x19.7-2.6 -748.0%  
Price / Book Value ratio x0.82.1 35.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,8338,067 72.3%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,1792,527 86.2%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m10,08919,477 51.8%  
Other income Rs m257407 63.0%   
Total revenues Rs m10,34619,884 52.0%   
Gross profit Rs m-7921,103 -71.8%  
Depreciation Rs m3612,519 14.3%   
Interest Rs m2,7565,227 52.7%   
Profit before tax Rs m-3,653-6,236 58.6%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713511 726.6%   
Tax Rs m125-125 -100.0%   
Profit after tax Rs m-65-5,580 1.2%  
Gross profit margin %-7.85.7 -138.7%  
Effective tax rate %-3.42.0 -170.7%   
Net profit margin %-0.6-28.7 2.3%  
BALANCE SHEET DATA
Current assets Rs m9,24011,014 83.9%   
Current liabilities Rs m9,99832,060 31.2%   
Net working cap to sales %-7.5-108.1 7.0%  
Current ratio x0.90.3 269.0%  
Inventory Days Days4695 48.8%  
Debtors Days Days6034 178.6%  
Net fixed assets Rs m10,12429,440 34.4%   
Share capital Rs m206705 29.2%   
"Free" reserves Rs m5,5822,043 273.3%   
Net worth Rs m7,7343,800 203.5%   
Long term debt Rs m4,8899,018 54.2%   
Total assets Rs m22,88246,510 49.2%  
Interest coverage x-0.3-0.2 168.4%   
Debt to equity ratio x0.62.4 26.6%  
Sales to assets ratio x0.40.4 105.3%   
Return on assets %11.8-0.8 -1,547.3%  
Return on equity %-0.8-146.9 0.6%  
Return on capital %22.3-3.7 -597.4%  
Exports to sales %3.037.9 8.0%   
Imports to sales %0.422.6 1.9%   
Exports (fob) Rs m3077,378 4.2%   
Imports (cif) Rs m434,406 1.0%   
Fx inflow Rs m3077,513 4.1%   
Fx outflow Rs m1255,649 2.2%   
Net fx Rs m1811,865 9.7%   
CASH FLOW
From Operations Rs m11,7541,682 698.9%  
From Investments Rs m-561-9,860 5.7%  
From Financial Activity Rs m-6,7626,644 -101.8%  
Net Cashflow Rs m4,432-1,535 -288.7%  

Share Holding

Indian Promoters % 39.6 32.3 122.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.6 163.0%  
FIIs % 16.8 3.3 509.1%  
ADR/GDR % 0.0 4.6 -  
Free float % 36.1 55.3 65.3%  
Shareholders   16,479 84,811 19.4%  
Pledged promoter(s) holding % 77.6 54.9 141.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  AJANTA PHARMA  SUVEN LIFE  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - STERLING BIOTECH COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS